These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21744122)

  • 1. VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration.
    Nakata I; Yamashiro K; Nakanishi H; Tsujikawa A; Otani A; Yoshimura N
    Jpn J Ophthalmol; 2011 Sep; 55(5):435-443. PubMed ID: 21744122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial.
    Ahmadieh H; Taei R; Riazi-Esfahani M; Piri N; Homayouni M; Daftarian N; Yaseri M
    Retina; 2011 Oct; 31(9):1819-26. PubMed ID: 21555967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation.
    Shirakata Y; Shiragami C; Yamashita A; Nitta E; Fujiwara A; Shiraga F
    Jpn J Ophthalmol; 2012 Nov; 56(6):599-607. PubMed ID: 22990616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.
    Abedi F; Wickremasinghe S; Richardson AJ; Makalic E; Schmidt DF; Sandhu SS; Baird PN; Guymer RH
    Ophthalmology; 2013 Jan; 120(1):115-21. PubMed ID: 23149126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.
    Abedi F; Wickremasinghe S; Richardson AJ; Islam AF; Guymer RH; Baird PN
    Ophthalmology; 2013 Aug; 120(8):1641-8. PubMed ID: 23582991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration.
    Hermann MM; van Asten F; Muether PS; Smailhodzic D; Lichtner P; Hoyng CB; Kirchhof B; Grefkes C; den Hollander AI; Fauser S
    Ophthalmology; 2014 Apr; 121(4):905-10. PubMed ID: 24365177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.
    Hagstrom SA; Ying GS; Maguire MG; Martin DF; ; Gibson J; Lotery A; Chakravarthy U;
    Ophthalmology; 2015 Aug; 122(8):1563-8. PubMed ID: 26028346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal Bevacizumab with or without Triamcinolone for Wet Age-related Macular Degeneration: Twelve-month Results of a Prospective, Randomized Investigation.
    Motarjemizadeh Q; Aidenloo NS; Abbaszadeh M; Sadrinia V
    Middle East Afr J Ophthalmol; 2018; 25(1):1-7. PubMed ID: 29899643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration.
    Boltz A; Ruiß M; Jonas JB; Tao Y; Rensch F; Weger M; Garhöfer G; Frantal S; El-Shabrawi Y; Schmetterer L
    Ophthalmology; 2012 Aug; 119(8):1615-20. PubMed ID: 22521084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The variable efficacy of intravitreal bevacizumab and triamcinolone acetonide for cystoid macular edema due to radiation retinopathy.
    Bakri SJ; Larson TA
    Semin Ophthalmol; 2015 Jul; 30(4):276-80. PubMed ID: 24251435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-year visual outcome of photodynamic therapy plus intravitreal bevacizumab with or without subtenon triamcinolone acetonide injections for polypoidal choroidal vasculopathy.
    Sakai T; Ohkuma Y; Kohno H; Hayashi T; Watanabe A; Tsuneoka H
    Br J Ophthalmol; 2014 Dec; 98(12):1642-8. PubMed ID: 25053762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration.
    Smailhodzic D; Muether PS; Chen J; Kwestro A; Zhang AY; Omar A; Van de Ven JP; Keunen JE; Kirchhof B; Hoyng CB; Klevering BJ; Koenekoop RK; Fauser S; den Hollander AI
    Ophthalmology; 2012 Nov; 119(11):2304-11. PubMed ID: 22840423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple therapy for anti-vascular endothelial growth factor nonresponders in neovascular age-related macular degeneration: impact of different photodynamic therapy parameters.
    Veritti D; Lanzetta P
    Ophthalmologica; 2013; 230(3):131-7. PubMed ID: 23948986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
    Ahmadieh H; Taei R; Soheilian M; Riazi-Esfahani M; Karkhaneh R; Lashay A; Azarmina M; Dehghan MH; Moradian S
    BMC Ophthalmol; 2007 Jun; 7():10. PubMed ID: 17555600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photodynamic therapy combined with intravitreal bevacizumab and sub-tenon triamcinolone acetonide injections for age-related macular degeneration.
    Yoshizawa C; Saito W; Hirose S; Kitamei H; Noda K; Ishida S
    Jpn J Ophthalmol; 2013 Jan; 57(1):68-73. PubMed ID: 23093314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study.
    Lim JY; Lee SY; Kim JG; Lee JY; Chung H; Yoon YH
    Acta Ophthalmol; 2012 Feb; 90(1):61-7. PubMed ID: 20337606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone.
    Yip PP; Woo CF; Tang HH; Ho CK
    Br J Ophthalmol; 2009 Jun; 93(6):754-8. PubMed ID: 19273471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration.
    McKibbin M; Ali M; Bansal S; Baxter PD; West K; Williams G; Cassidy F; Inglehearn CF
    Br J Ophthalmol; 2012 Feb; 96(2):208-12. PubMed ID: 21558292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab as the primary treatment of clinically significant macular edema.
    Liu Q; Hu Y; Yu H; Yuan L; Hu J; Atik A; Guan M; Li D; Li X; Tang S
    Retina; 2015 Feb; 35(2):272-9. PubMed ID: 25105313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.